Question
CASTRATION-SENSITIVE PROSTATE CANCER
Do Black patients with metastatic castration-sensitive prostate cancer have worse outcomes than White patients when treated with systemic androgen deprivation therapy combined with a first- or a second-generation androgen receptor pathway inhibitor?